Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROEL QUERUBIN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1124154323
CMS profile
278273
Location
MARIETTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,669.55

227 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,551.30 225
Education $118.25 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 227 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROEL QUERUBIN

NPI 1124154323 · CMS profile ID 278273

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

MARIETTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 227 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124154323?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROEL QUERUBIN, NPI 1124154323, CMS profile ID 278273. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 227 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124154323?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROEL QUERUBIN, NPI 1124154323, CMS profile ID 278273. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 227 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124154323?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROEL QUERUBIN, NPI 1124154323, CMS profile ID 278273, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 227 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124154323?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

227 matching records · $4,669.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 227 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 227.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $4.7405/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157397 CMS
Amgen Inc. $27.4705/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034248 CMS
Radius Health, Inc. $31.9605/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089988078 CMS
ABBVIE INC. $7.7405/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335328 CMS
UCB, Inc. $9.7005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143024683 CMS
UCB, Inc. $15.7105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143024685 CMS
UCB, Inc. $20.1805/01/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155576323 CMS
Amgen Inc. $8.8904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034242 CMS
AstraZeneca Pharmaceuticals LP $22.5804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110538665 CMS
AstraZeneca Pharmaceuticals LP $10.4304/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110555684 CMS
E.R. Squibb & Sons, L.L.C. $21.7304/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101496075 CMS
Novartis Pharmaceuticals Corporation $4.0104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157395 CMS
Lilly USA, LLC $18.5004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135375800 CMS
ABBVIE INC. $5.4604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335324 CMS
GlaxoSmithKline, LLC. $14.4604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116728202 CMS
Amgen Inc. $22.3104/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034282 CMS
Aurinia Pharma U.S., Inc. $28.6304/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150689967 CMS
Amgen Inc. $28.3604/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034182 CMS
Amgen Inc. $12.8704/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034176 CMS
Janssen Biotech, Inc. $26.3504/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078548309 CMS
ABBVIE INC. $14.7104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335312 CMS
ABBVIE INC. $0.9104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335316 CMS
ABBVIE INC. $1.0104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335320 CMS
Amgen Inc. $29.1404/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034236 CMS
Janssen Biotech, Inc. $18.2504/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078548067 CMS
Mallinckrodt Hospital Products Inc. $28.7404/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145122721 CMS
Amgen Inc. $17.2204/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034086 CMS
Genentech USA, Inc. $13.9003/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133100682 CMS
ABBVIE INC. $25.5203/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335308 CMS
Novartis Pharmaceuticals Corporation $24.5003/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157381 CMS
Amgen Inc. $24.5303/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117660404 CMS
Amgen Inc. $28.9103/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034168 CMS
ANI Pharmaceuticals, Inc. $27.5403/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091138986 CMS
ABBVIE INC. $14.0403/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335304 CMS
Lilly USA, LLC $20.4003/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135363273 CMS
UCB, Inc. $30.0403/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143024681 CMS
ABBVIE INC. $19.3203/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335300 CMS
PFIZER INC. $16.0603/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131272731 CMS
GlaxoSmithKline, LLC. $13.8303/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116607590 CMS
ABBVIE INC. $21.0703/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335296 CMS
Janssen Biotech, Inc. $99.0003/05/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078545895 CMS
Janssen Biotech, Inc. $25.9103/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078546689 CMS
Janssen Biotech, Inc. $1.0403/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078548282 CMS
Amgen Inc. $31.2503/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034274 CMS
Amgen Inc. $16.7902/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034162 CMS
Amgen Inc. $16.8502/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116034140 CMS
Janssen Biotech, Inc. $27.6602/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078548231 CMS
ABBVIE INC. $34.0002/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105335291 CMS
Janssen Biotech, Inc. $17.9502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078547322 CMS
PFIZER INC. $18.5602/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131052718 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,765.45 213
PY2020 $1,936.93 124
PY2021 $2,250.94 133
PY2022 $3,071.44 182
PY2023 $4,243.37 226
PY2024 $4,669.55 227
PY2025 $4,512.97 234

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $377,962.29 41
PY2024 Recipient $114.46 1
PY2024 Principal investigator $401,977.94 43
PY2023 Principal investigator $218,427.52 29
PY2022 Principal investigator $97,151.73 49
PY2021 Recipient $16.15 1
PY2021 Principal investigator $194,091.85 47
PY2020 Principal investigator $117,660.95 38
PY2019 Principal investigator $88,382.60 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,077.30 12/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202527574
Principal investigator 1 ABBVIE INC. $192.10 12/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527576
Principal investigator 1 GlaxoSmithKline, LLC. $11,556.90 11/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098093
Principal investigator 1 ABBVIE INC. $3,176.50 11/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520285
Principal investigator 1 GlaxoSmithKline, LLC. $2,600.00 10/28/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150880
Principal investigator 1 Eli Lilly and Company $16,380.00 10/21/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187875993
Principal investigator 1 GlaxoSmithKline, LLC. $4,823.10 10/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150858
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,020.00 09/24/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285852
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 09/24/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285854
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $937.50 09/24/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285856
Principal investigator 1 GlaxoSmithKline, LLC. $2,150.00 09/10/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098081
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 09/10/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150874
Principal investigator 1 ABBVIE INC. $2,027.30 09/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202507301
Principal investigator 1 GlaxoSmithKline, LLC. $0.90 09/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150855
Principal investigator 1 ABBVIE INC. $2,615.00 08/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501420
Principal investigator 1 ABBVIE INC. $2,353.00 08/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202501466
Principal investigator 1 GlaxoSmithKline, LLC. $3,170.70 08/01/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150883
Principal investigator 1 ABBVIE INC. $7,473.70 07/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494485
Principal investigator 1 GlaxoSmithKline, LLC. $2,405.70 07/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150862
Principal investigator 1 GlaxoSmithKline, LLC. $3,649.50 06/04/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150870
Principal investigator 1 GlaxoSmithKline, LLC. $6,044.40 05/09/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192098087
Principal investigator 1 ABBVIE INC. $1,139.70 05/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202482703
Principal investigator 1 ABBVIE INC. $4,256.20 05/06/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481399
Principal investigator 1 ABBVIE INC. $2,152.80 04/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202471451
Principal investigator 1 ABBVIE INC. $1,139.70 04/03/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471459
Principal investigator 1 GlaxoSmithKline, LLC. $5,564.70 04/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192151442
Principal investigator 1 UCB SA $11,550.00 03/27/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657714
Principal investigator 1 ABBVIE INC. $4,741.60 03/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202459702
Principal investigator 1 ABBVIE INC. $2,278.90 03/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202459706
Principal investigator 1 GlaxoSmithKline, LLC. $5,810.40 03/07/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192151438
Principal investigator 1 UCB SA $719.98 03/05/2025 Non-covered Recipient Entity
ATLANTA CENTER FOR CLINICAL RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657706
Principal investigator 1 ABBVIE INC. $4,677.00 02/06/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202446972
Principal investigator 1 ABBVIE INC. $1,977.30 02/06/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202446995
Principal investigator 1 GlaxoSmithKline, LLC. $33,945.30 02/05/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192150866
Principal investigator 1 Eli Lilly and Company $84,351.00 01/28/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875277
Principal investigator 1 UCB SA $3,480.00 01/28/2025 Non-covered Recipient Entity
Marietta Rheumatology Associates, Pc
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657488
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $104,337.22 01/21/2025 Non-covered Recipient Entity
Atlanta Research Center For Rheumatology
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235998842
Principal investigator 1 GlaxoSmithKline, LLC. $9,910.00 01/17/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR RHEUMATOLOGY
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192151445
Principal investigator 1 Eli Lilly and Company $2,017.19 01/08/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187877125
Principal investigator 1 ABBVIE INC. $1,672.30 01/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202433546
Principal investigator 1 ABBVIE INC. $4,547.40 01/02/2025 Non-covered Recipient Entity
ATLANTA RESEARCH CENTER FOR
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202433566